A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

NCT05273749 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

457

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibromyalgia

Interventions

DRUG: TNX-102 SL Tablet, 5.6 mg
DRUG: Placebo SL Tablet

Sponsor

Tonix Pharmaceuticals, Inc.